From Alchemy to IPO The Business of Biotechnology
CHEAP,Discount,Buy,Sale,Bestsellers,Good,For,REVIEW, From Alchemy to IPO The Business of Biotechnology,Wholesale,Promotions,Shopping,Shipping,From Alchemy to IPO The Business of Biotechnology,BestSelling,Off,Savings,Gifts,Cool,Hot,Top,Sellers,Overview,Specifications,Feature,on sale,From Alchemy to IPO The Business of Biotechnology From Alchemy to IPO The Business of Biotechnology
From Alchemy to IPO The Business of Biotechnology Overview
It is impossible to dispute the extraordinary impact biotechnology is having on our everyday lives. From Alchemy to IPO presents the dramatic story of the revolutionary and controversial business of inventing new cures and blockbuster drugs and a look at how biotech progress is generating powerful profit opportunities on all tiers of business and investment.Written by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the '70s to today's heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market, and describes advances, such as deciphering the genetic code and gene therapy, that just may lead biotech to a higher realm altogether. This is the first book to accurately record the inner workings of an industry-biotechnology-that's on the verge of living up to its monumental promise to change the world as we know it.
From Alchemy to IPO The Business of Biotechnology Specifications
Despite unnerving swings in individual stock valuations--or perhaps because of them--many knowledgeable observers still believe the 21st century will ultimately earn its stripes as the Age of Biotech. Cynthia Robbins-Roth, named by Forbes magazine as one of the industry's top insiders, certainly is among them. And in From Alchemy to IPO, she persuasively argues investors better take heed because they ain't seen nothin' yet. "Most of us think of biotech as medicine or genetically engineered crops," writes Robbins-Roth. But in the very near future, she continues, it also "may make it possible for humans to reach the stars and to change the environment on other planets." Think that's far-fetched? She says developments like this are already in early stages and, in a deliberately proselytizing manner, traces their roots to the current business nitty-gritty, finally focusing on the long-term moneymaking potential. "The biotech world will never be an easy place for investors," she cautions, but with hundreds of ongoing projects "poised to power into the marketplace," there will be plenty of "opportunities for investors and employees alike." Recommended for readers seeking an informed tutorial on this field of the future. --Howard Rothman
